Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» upadacatinib
upadacatinib
Go or no go? Abbvie, Roche and Kala await key decisions
Go or no go? Abbvie, Roche and Kala await key decisions
EP Vantage
FDA
AbbVie
upadacatinib
Roche
Ignyta
entrectinib
Kala Pharmaceuticals
KPI-121
dry eye disease
Flag link:
5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
Motley Fool
Vertex Pharmaceuticals
VX-445
tezacaftor/ivacaftor
AbbVie
upadacatinib
Daiichi Sankyo
trastuzumab deruxtecan
Celgene
liso-cel
Novartis
LY3298176
Flag link:
2 Things Investors Are Missing About AbbVie
2 Things Investors Are Missing About AbbVie
Motley Fool
AbbVie
ABBV-599
Humira
risankizumab
upadacatinib
Imbruvica
Venclexta
Orilissa
Flag link:
AbbVie’s JAK inhibitor upadacitinib gets Priority Review
AbbVie’s JAK inhibitor upadacitinib gets Priority Review
Pharmaforum
AbbVie
upadacatinib
FDA
priority review
rheumatoid arthritis
Humira
Flag link:
5 Experimental New Drugs That Could Be Worth $47 Billion
5 Experimental New Drugs That Could Be Worth $47 Billion
Motley Fool
GSK2857916
GSK
brolucizumab
Novartis
aducanumab
Biogen
upadacatinib
AbbVie
VX-659 + tezacaftor + ivacaftor
Vertex Pharmaceuticals
Flag link:
